AAP
HRMY icon

Arax Advisory Partners’s Harmony Biosciences HRMY Stock Holding History

Arax Advisory Partners’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$146K Buy
4,003
+3,806
+1,932% +$120K ﹤0.01% 2460
2026
Q1 		$5.52K Buy
197
+55
+39% +$1.8K ﹤0.01% 2734
2025
Q4 		$5.31K Sell
142
-7,382
-98% -$243K ﹤0.01% 2813
2025
Q3 		$207K Buy
7,524
+7,416
+6,867% +$255K ﹤0.01% 1251
2025
Q2 		$3.41K Buy
108
+99
+1,100% +$3.19K ﹤0.01% 2373
2025
Q1 		$299 Sell
9
-75
-89% -$2.69K ﹤0.01% 2577
2024
Q4 		$2.89K Sell
84
-28
-25% -$962 ﹤0.01% 1918
2024
Q3 		$4.48K Hold
112
– – ﹤0.01% 1764
2024
Q2 		$3.38K Buy
+112
New +$3.37K ﹤0.01% 1764

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arax Advisory Partners's HRMY Position: Q2 2026 in Review

Arax Advisory Partners increased its Harmony Biosciences (HRMY) stake by 1,932% in Q2 2026, buying an estimated $120K and bringing the position to 4,003 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #2460.

Arax Advisory Partners first reported a position in HRMY in Q2 2024 and has held it in 9 quarters since. The position peaked at $207K in Q3 2025. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Arax Advisory Partners held 4,003 shares of Harmony Biosciences worth $146K as of Q2 2026.
  • Arax Advisory Partners bought 3,806 Harmony Biosciences shares in Q2 2026, an estimated $120K.
  • Harmony Biosciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2460 holding.
  • Arax Advisory Partners first reported a position in Harmony Biosciences in Q2 2024 and has held it in 9 quarters since.
  • Arax Advisory Partners's Harmony Biosciences position peaked at $207K in Q3 2025.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.